| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
101,800,000 |
| Market
Cap: |
2.25(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.13 - $82.51 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NovoCure is an oncology company with a platform technology called Tumor Treating Fields. Co. is focusing on commercial adoption of Optune and NovoTTF-100L. Optune is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in combination with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Co. also has approval to market Optune for the treatment of GBM in the European Union, Japan and certain other countries. NovoTTF-100L is approved by the FDA to treat malignant pleural mesothelioma in combination with chemotherapies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
10,224 |
13,200 |
434,026 |
| Total Sell Value |
$0 |
$164,332 |
$235,406 |
$41,239,900 |
| Total People Sold |
0 |
2 |
4 |
10 |
| Total Sell Transactions |
0 |
6 |
11 |
52 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Leonard Frank X |
President, CNS Cancers US |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
18,621 |
64,779 |
|
- |
|
| Weinberg Uri |
Chief Innovation Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
12,992 |
56,278 |
|
- |
|
| Groenhuysen Wilhelmus Cm |
Chief Operating Officer |
• – – |
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
21,653 |
186,779 |
|
- |
|
| Benaim Ely |
Chief Medical Officer |
• – – |
2023-01-06 |
4 |
A |
$62.31 |
$6,106 |
D/D |
98 |
28,770 |
|
- |
|
| Groenhuysen Wilhelmus Cm |
Chief Operating Officer |
• – – |
2023-01-06 |
4 |
A |
$62.31 |
$6,355 |
D/D |
102 |
165,126 |
|
- |
|
| Ben Arye Barak |
General Counsel |
• – – |
2023-01-06 |
4 |
A |
$62.31 |
$9,346 |
D/D |
150 |
17,152 |
|
- |
|
| Burke William Patrick |
Chief Human Resources Officer |
• – – |
2023-01-06 |
4 |
A |
$62.31 |
$6,729 |
D/D |
108 |
55,594 |
|
- |
|
| Cordova Ashley |
Chief Financial Officer |
• – – |
2023-01-06 |
4 |
A |
$62.31 |
$4,112 |
D/D |
66 |
74,442 |
|
- |
|
| Danziger Asaf |
Chief Executive Officer |
• • – |
2023-01-06 |
4 |
A |
$62.31 |
$2,430 |
D/D |
39 |
13,622 |
|
- |
|
| Danziger Asaf |
Chief Executive Officer |
• • – |
2023-01-05 |
4 |
AS |
$108.00 |
$23,106,230 |
D/D |
(212,500) |
13,583 |
|
-32% |
|
| Danziger Asaf |
Chief Executive Officer |
• • – |
2023-01-05 |
4 |
OE |
$7.15 |
$1,627,125 |
D/D |
212,500 |
201,083 |
|
- |
|
| Weinberg Uri |
Chief Science Officer |
• – – |
2023-01-05 |
4 |
AS |
$108.00 |
$945,756 |
D/D |
(8,143) |
43,286 |
|
-32% |
|
| Weinberg Uri |
Chief Science Officer |
• – – |
2023-01-05 |
4 |
OE |
$47.04 |
$91,540 |
D/D |
1,946 |
49,050 |
|
- |
|
| Shah Pritesh |
Chief Commercial Officer |
• – – |
2023-01-05 |
4 |
AS |
$108.00 |
$41,796 |
D/D |
(387) |
82,843 |
|
-32% |
|
| Leonard Frank X |
President, CNS Cancers US |
• – – |
2023-01-05 |
4 |
AS |
$108.00 |
$4,434,654 |
D/D |
(39,507) |
46,158 |
|
-32% |
|
| Leonard Frank X |
President, CNS Cancers US |
• – – |
2023-01-05 |
4 |
OE |
$7.15 |
$541,697 |
D/D |
35,209 |
53,341 |
|
- |
|
| Cordova Ashley |
Chief Financial Officer |
• – – |
2022-12-02 |
4 |
OE |
$7.15 |
$14,300 |
D/D |
2,000 |
74,376 |
|
- |
|
| Leonard Frank X |
President, CNS Cancers US |
• – – |
2022-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,830 |
50,456 |
|
- |
|
| Leonard Frank X |
President, CNS Cancers US |
• – – |
2022-10-13 |
4 |
AS |
$76.01 |
$513,372 |
D/D |
(6,754) |
43,626 |
|
-0% |
|
| Leonard Frank X |
President, CNS Cancers US |
• – – |
2022-10-06 |
4 |
AS |
$84.37 |
$569,835 |
D/D |
(6,754) |
50,380 |
|
-1% |
|
| Leonard Frank X |
President, CNS Cancers US |
• – – |
2022-09-29 |
4 |
AS |
$77.35 |
$522,422 |
D/D |
(6,754) |
57,134 |
|
11% |
|
| Leonard Frank X |
President, CNS Cancers US |
• – – |
2022-09-22 |
4 |
AS |
$77.00 |
$520,058 |
D/D |
(6,754) |
63,888 |
|
26% |
|
| Leonard Frank X |
Chief Development Officer |
• – – |
2022-09-15 |
4 |
AS |
$87.31 |
$1,086,222 |
D/D |
(12,271) |
70,642 |
|
2% |
|
| Leonard Frank X |
Chief Development Officer |
• – – |
2022-09-15 |
4 |
OE |
$7.15 |
$39,447 |
D/D |
5,517 |
82,913 |
|
- |
|
| Leonard Frank X |
Chief Development Officer |
• – – |
2022-09-09 |
4 |
AS |
$88.00 |
$163,944 |
D/D |
(1,863) |
84,150 |
|
-1% |
|
917 Records found
|
|
Page 4 of 37 |
|
|
0.98 (4.24%) 
